From: Malaria and risk of lymphoid neoplasms and other cancer: a nationwide population-based cohort study
Malaria patients, all sourcesa (N = 4125)b | Matched comparator cohort from the general population (N = 66,997) | |
Sex, female, n (%) | 1622 (39.3) | 26,991 (40.3) |
Age | ||
Age at start of follow-up, mean (± SD) years | 34.7 (± 18.5) | 35.5 (± 18.9) |
Attained age at end of follow-up, mean (± SD) years | 48.0 (± 18.7) | 49.6 (± 19.0) |
Children < 18 y, at inclusion, n (%) | 676 (16.4) | 9627 (14.4) |
Age ≥ 65 y, at inclusion, n (%) | 273 (6.6) | 5091 (7.6) |
Follow-up | ||
Total follow-up, person-years | 54,739 | 943,828 |
Average follow-up, person-years (SD) | 13.3 (± 8.3) | 14.1 (± 8.4) |
Country of birthc | ||
Sub-Saharan Africa, n (%) | 1307 (31.7) | 12,758 (19.0) |
Other low-endemic regions, n (%) | 295 (7.2) | 4899 (7.3) |
Sweden/non-endemic region, n (%) | 2523 (61.1) | 49,332 (73.6) |
Co-infections | ||
HIV before/at inclusion, or during follow-upd, n (%) | 54 (1.3), 49 (1.2) | 228 (0.3), 164 (0.2)3 |
Hepatitis B before/at inclusion, or during follow-upe, n (%) | 26 (0.6), 39 (1.0) | 235 (0.4), 307 (0.5) |
Hepatitis C before/at inclusion, or during follow-up, n (%) | 14 (0.3), 19 (0.5) | 124 (0.2), 333 (0.5) |
Incident lymphoid neoplasms, n (%) | 20 (0.48) | 304 (0.45) |
Lymphoid neoplasm within 1 year, n (%) | 0 | 17 (5.6) |
Lymphoid neoplasm after 1–5 y, n (%) | 5 (25.0) | 65 (21.4) |
Lymphoid neoplasm after > 5 y, n (%) | 15 (75.0) | 222 (73.0) |
Malaria patients, all sources (N = 4027)f | Matched comparator cohort from the general population (N = 63,588) | |
Incident cancerg, n (%) | 202 (5.0) | 3993 (6.2) |
Total follow-up, person-years | 55,361 | 924,517 |
Average follow-up, person-years (SD) | 13.7 (± 8.1) | 14.5 (± 8.3) |